Review





Similar Products

aim100  (MedChemExpress)
93
MedChemExpress aim100
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim100, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim100/product/MedChemExpress
Average 93 stars, based on 1 article reviews
aim100 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
aim 100 t5092  (TargetMol)
93
TargetMol aim 100 t5092
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim 100 T5092, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim 100 t5092/product/TargetMol
Average 93 stars, based on 1 article reviews
aim 100 t5092 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
aim 100  (MedChemExpress)
93
MedChemExpress aim 100
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim 100, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim 100/product/MedChemExpress
Average 93 stars, based on 1 article reviews
aim 100 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
aim v medium supplemented with 100 u/ml rh il-2  (R&D Systems)
90
R&D Systems aim v medium supplemented with 100 u/ml rh il-2
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim V Medium Supplemented With 100 U/Ml Rh Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim v medium supplemented with 100 u/ml rh il-2/product/R&D Systems
Average 90 stars, based on 1 article reviews
aim v medium supplemented with 100 u/ml rh il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
aim team  (fluidigm)
99
fluidigm aim team
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim Team, supplied by fluidigm, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim team/product/fluidigm
Average 99 stars, based on 1 article reviews
aim team - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
5 6 diphenyl n  (Tocris)
93
Tocris 5 6 diphenyl n
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
5 6 Diphenyl N, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/5 6 diphenyl n/product/Tocris
Average 93 stars, based on 1 article reviews
5 6 diphenyl n - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
aim-100  (Amgen)
90
Amgen aim-100
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim 100, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim-100/product/Amgen
Average 90 stars, based on 1 article reviews
aim-100 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
aim  (Selleck Chemicals)
91
Selleck Chemicals aim
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim/product/Selleck Chemicals
Average 91 stars, based on 1 article reviews
aim - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
aim-100  (Tocris)
90
Tocris aim-100
a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, <t>AIM100</t> and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.
Aim 100, supplied by Tocris, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aim-100/product/Tocris
Average 90 stars, based on 1 article reviews
aim-100 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, AIM100 and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer

doi: 10.1038/s41467-025-67197-3

Figure Lengend Snippet: a Representative images of TNK2 IHC staining and CT scans in PDAC patients treated with neoadjuvant therapy. b Association between TNK2 expression level and neoadjuvant chemotherapy response. Counts of PR, SD and PD are shown for TNK2-low ( n = 22) and TNK2-high ( n = 23) tumors (total n = 45 independent experiments). The overall association across the three response categories was tested by Pearson’s χ² test (two-sided); p = 0.0046. For the binary summary, NPD = PR + SD versus PD (comparison indicated in the panel). PR partial remission, SD stable disease, PD progressive disease, NPD non-progressive disease. c The synergy score of GEM, AIM100 and αPD-1 were analyzed through Synergy finder for the treatment of orthotopic transplantation mouse model. The representative tumor images ( d up) and the representative PET-CT images ( d down, e ) of the KPC GEMM mouse which treated with control, AG, AIM100 and AG, AG and aPD-1, or AG, AIM100 and αPD-1, at the experimental endpoint before the therapy ending stage ( n = 3 independent experiments). f The pancreas weights of the mouse groups described in ( d ) ( n = 3 independent experiments). g Kaplan–Meier curves for tumor free survival in the mouse groups in ( d ). Flow cytometry analysis showing the proportions of CD8 + T cells ( h ), TNFα + CD8 + T cells ( i ), and PD-1 + CD8 + T ( j ) cells in the mouse groups in ( d ). k The representative mIHC images of tumor issues (CK19 in cyan, Ki67 in red, and nuclei in blue) from the mouse groups in ( d ). l The representative mIHC images of tumor issues from the mouse groups in ( d ) at the experimental endpoint, with TNK2 stained in blue, CD8 in red, CK19 in purple, and nuclei in blue. Statistical significance was determined by log-rank (Mantel–Cox) test in survival analysis ( g ) or one-way ANOVA followed by Tukey’s multiple comparisons test ( e , f , h – l ). All tests were two sided ( e – l ). Data represent mean ± s.d. Source data are provided as a Source Data file.

Article Snippet: Additionally, an anti-PD-1 antibody (200 μg/100 μl per mouse, Bio X Cell, #BE0146) was injected on the 4th, 7th, and 10th days, along with AIM100 (6 mg/kg, MCE, HY-15290) every four days or (R)-9b (25 mg/kg, Sigma-Aldrich, SML2073) every five days through intraperitoneal injection.

Techniques: Immunohistochemistry, Expressing, Comparison, Transplantation Assay, Positron Emission Tomography-Computed Tomography, Control, Flow Cytometry, Staining